Applied Therapeutics, a clinical-stage biopharmaceutical company, is under heightened scrutiny following the issuance of a November 2024 Warning Letter1 from the US Food and Drug Administration (FDA) on the heels of a routine preapproval bioresearch monitoring (BIMO) inspection.2 FDA’s BIMO program is designed to ensure the integrity of data submitted to FDA, and to protect the rights, safety and welfare of research participants.
Elizabeth Caruso
As seen in:
The Portland Press Herald,
JD Supra,
Lexology,
Kennebec Journal,
Mondaq,
Mount Desert Islander,
LexBlog
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Elizabeth
Contact Elizabeth, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack